Naloxone
(a)
is a kappa receptor agonist
(b)
has a high oral bioavailability
(c)
has an elimination half-life of 1–2 h
(d)
causes pulmonary oedema
(e)
prevents conversion of angiotensin I to angiotensin II
(a) false (b)
false (c)
false (d)
true (e)
false
No comments:
Post a Comment